Free Trial
NASDAQ:HOWL

Werewolf Therapeutics (HOWL) Stock Price, News & Analysis

Werewolf Therapeutics logo
$1.93 -0.12 (-5.85%)
(As of 04:32 PM ET)

About Werewolf Therapeutics Stock (NASDAQ:HOWL)

Key Stats

Today's Range
$1.91
$2.10
50-Day Range
$1.81
$3.63
52-Week Range
$1.66
$8.19
Volume
563,898 shs
Average Volume
376,794 shs
Market Capitalization
$86.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Werewolf Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
73rd Percentile Overall Score

HOWL MarketRank™: 

Werewolf Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 367th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Werewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Werewolf Therapeutics has received no research coverage in the past 90 days.

  • Read more about Werewolf Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.93) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Werewolf Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Werewolf Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Werewolf Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Werewolf Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.76% of the float of Werewolf Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Werewolf Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Werewolf Therapeutics has recently increased by 58.51%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Werewolf Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Werewolf Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.76% of the float of Werewolf Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Werewolf Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Werewolf Therapeutics has recently increased by 58.51%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Werewolf Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Werewolf Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    19 people have searched for HOWL on MarketBeat in the last 30 days. This is an increase of 850% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Werewolf Therapeutics' insider trading history.
Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOWL Stock News Headlines

Research Analysts Offer Predictions for HOWL FY2024 Earnings
Why buying gold might be a mistake
Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.
Werewolf Therapeutics Advances Innovative Cytokine Therapies
Werewolf Therapeutics sees cash runway through 2Q26
Werewolf Therapeutics presents preclinical, clinical data on WTX-330
See More Headlines

HOWL Stock Analysis - Frequently Asked Questions

Werewolf Therapeutics' stock was trading at $3.86 at the beginning of the year. Since then, HOWL shares have decreased by 49.2% and is now trading at $1.96.
View the best growth stocks for 2024 here
.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.06. Werewolf Therapeutics had a negative net margin of 578.80% and a negative trailing twelve-month return on equity of 58.83%.

Werewolf Therapeutics (HOWL) raised $101 million in an initial public offering on Friday, April 30th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Werewolf Therapeutics' top institutional shareholders include Walleye Capital LLC (0.24%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Ra Capital Management, LP and Reid Leonard.
View institutional ownership trends
.

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Werewolf Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
11/10/2021
Today
11/14/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HOWL
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$15.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+512.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-37,370,000.00
Net Margins
-578.80%
Pretax Margin
-1,834.55%

Debt

Sales & Book Value

Annual Sales
$19.94 million
Book Value
$2.01 per share

Miscellaneous

Free Float
35,160,000
Market Cap
$87.34 million
Optionable
Optionable
Beta
0.41
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:HOWL) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners